Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Colorectal Neoplasms 27Neoplasm Metastasis 5Advanced Solid Tumors 5Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors (Excluding Breast Cancer) 2Urologic Diseases 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Refractory Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Kidney Diseases 1Head and Neck Neoplasms 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT03274882 2024-07-25

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

Servier

Phase 2 Completed
26 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡